CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; and AlloSure Heart, a dd-cfDNA test to identify underlying cell injury leading to organ rejection. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables precision in HLA typing at a low to intermediate resolution for samples that uses real-time polymerase chain reaction methodology; and TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Ottr, a transplant patient tracking software; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors. CareDx, Inc. has a license agreement with Illumina, Inc. for the distribution, development and commercialization rights to NGS products and technologies; and Cibiltech SAS to commercialize KidneyCare iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in South San Francisco, California.
IPO Year: 2014
Exchange: NASDAQ
Website: caredx.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/28/2024 | $28.00 | Underweight | Wells Fargo |
8/19/2024 | $40.00 | Neutral → Buy | BTIG Research |
5/13/2024 | Outperform → Mkt Perform | Raymond James | |
5/1/2024 | $15.00 | Hold → Buy | Craig Hallum |
11/9/2023 | $10.00 | Equal-Weight → Overweight | Stephens |
8/15/2023 | $12.00 | Mkt Perform → Outperform | Raymond James |
5/11/2023 | Buy → Neutral | BTIG Research | |
3/7/2023 | $19.00 → $9.00 | Overweight → Equal-Weight | Stephens |
3/3/2023 | $26.00 → $9.00 | Buy → Hold | Craig Hallum |
3/3/2023 | Strong Buy → Mkt Perform | Raymond James |
CareDx, Inc. (NASDAQ:CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on September 12, 2024, CareDx granted an option to purchase 100,651 shares of CareDx's common stock (the "Kennedy Inducement Option") and 70,101 restricted stock units (the "Kennedy Inducement RSUs") to Keith S. Kennedy, CareDx's newly appointed Chief Operating Officer, and granted an option to purchase 75,488 shares of CareDx's common stock (the "Meng Inducement Option" and, together with the Kennedy Inducement Option
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, as an inducement material to entering into employment with CareDx, on September 12, 2024, 14 new employees were awarded restricted stock units (RSUs) for an aggregate of 44,000 shares of common stock. The RSUs were granted pursuant to the Company's 2019 Inducement Equity Incentive Plan, which was approved by the Compensation Committee of the Board of Directors in August 2019 under Nasdaq Listing Rule 5635(c)(4). RSUs
CareDx Announces Addition of Operational and Commercial Expertise to Lead Key Strategic Initiatives Marica Grskovic Appointed Chief Strategy Officer to Lead Corporate Development CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the appointment of two senior executives who will lead key initiatives as the Company advances its long-term strategic growth plan. CareDx will be sharing its long-term growth strategy during an Investor Day in October 2024. Keith Kennedy brings more than 20 years of experience and e
CMS Recognizes the Importance of Surveillance Testing for Early Detection of Allograft Rejection CMS to Retire Proposed Draft Policy that Would Have Restricted Coverage CareDx, Inc. (NASDAQ:CDNA) - The Transplant Company™ – today announced that the Centers for Medicare and Medicaid Services (CMS) has announced its plan to retire a draft LCD that would have restricted coverage for non-invasive blood-based surveillance testing for allograft rejection. Combined with the February 2024 removal of restrictive language in the accompanying Billing Article and based on discussions with CMS, CareDx believes that longstanding coverage for AlloSure®, AlloMap® and HeartCare® has effectively been res
CareDx, Inc. (NASDAQ:CDNA) – today announced financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights Reported total revenue of $92.3 million, an increase of 31% year-over-year. Grew Testing Services volume to 43,700 tests, an increase of 17% year-over-year. Reported GAAP net loss of $1.4 million, non-GAAP net income of $13.6 million, and positive adjusted EBITDA of $12.9 million, a significant improvement from the second quarter 2023. Generated $18.9 million cash from operations. Ended the quarter with cash, cash equivalents, and marketable securities of approximately $228.9 million, with no debt. Raised 2024 guidance for annua
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the second quarter 2024 after market close on Wednesday, July 31, 2024. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-267-6316 for domestic callers or 1-203-518-9783 for international callers. Please reference Conference ID: CareDx. To listen to a live webcast, pl
Surveillance Monitoring with Both AlloSure Kidney and the AlloView AI-Enabled Risk Prediction Model Improves the Detection of All Types of Allograft Rejection AlloSure Kidney Detected Subclinical Rejection in Clinically Stable Patients and AlloSure Kidney dd-cfDNA Levels were Elevated Prior to Biopsy Proven Rejection in an Analysis of Patients Receiving Consecutive Biopsies AlloSure dd-cfDNA Levels Declined in Response to Immunosuppression Treatment Suggesting There May be Utility in Therapy Monitoring for Recovery or Progression CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value he
CareDx Reiterates Position that it Does Not Infringe Natera's ‘544 Patent Injunction Motion has No Impact on CareDx's Business or Patient and Clinician Access to AlloSure or AlloMap CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today responded to Natera, Inc.'s filing of a motion for an injunction related to patent 11,111,544 (the ‘544 patent). The motion seeks to stop CareDx from using a prior AlloSure® process that Natera alleged infringed the ‘544 patent. That process is no longer in effect. As CareDx informed Nat
CareDx, Inc. (NASDAQ:CDNA), The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in two upcoming investor conferences. CareDx's management is scheduled to present at the: Jefferies Global Healthcare Conference on Thursday, June 6, 2023, at 11:30 AM PT / 2:30 PM ET. Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2023, at 1:00 PM PT / 4:00 PM ET. To listen to the webcast, please visit the Events & Presentations section of CareDx's In
HeartCare Results Effectively Stratified Patients at Highest Risk for Acute Cellular Rejection Cardiologists Performed the Fewest Biopsies After Dual Negative HeartCare Results Compared to Single or Dual Positive Results Two-Year Clinical Outcomes Data Demonstrate Excellent Survival and Allograft Function CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced findings from the SHORE (Surveillance HeartCare Outcomes Registry) study, one of the largest heart transplant stud
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the second quarter 2024 after market close on Wednesday, July 31, 2024. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-267-6316 for domestic callers or 1-203-518-9783 for international callers. Please reference Conference ID: CareDx. To listen to a live webcast, pl
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2024 after market close on Thursday, May 9, 2024. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-343-4136 for domestic callers or 1-203-518-9843 for international callers. Please reference Conference ID: CareDx. To listen to a live webcast, please
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the fourth quarter and full year 2023 after market close on Wednesday, February 28, 2024. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-877-704-4453 for domestic callers or 1-201-389-0920 for international callers. Please reference Conference ID: CareDx. To listen to
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the third quarter 2023 after market close on Wednesday, November 8th, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-267-6316 for domestic callers or 1-203-518-9783 for international callers. Please reference Conference ID: CareDx. To listen to a live webcast
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the second quarter 2023 after market close on Tuesday, August 8th, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-877-300-8521 for domestic callers or 1-412-317-6026 for international callers. Please reference Conference ID: 10181676. To listen to a live webcast,
MediGO Platform Aims to Improve Access to Donated Organs and Shorten Transplant Wait Times Acquisition Expands CareDx Digital Health Portfolio and Establishes Footprint in OPO Market CareDx, Inc. (NASDAQ:CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the acquisition of MediGO, Inc. in a strategic move to expand its digital health portfolio to serve the organ procurement organization (OPO) market while also bolstering its pre-transplant offerings aimed at shortening transplant wait times and increasing access to d
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2023 after market close on Wednesday, May 10, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-732-8470 for domestic callers or 1-212-231-2912 for international callers. Please reference Conference ID: 22026935. To listen to a live webcast, pl
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the fourth quarter and full year 2022 after market close on Monday, February 27, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-877-704-4453 for domestic callers or 1-201-389-0920 for international callers. Please reference Conference ID: 13736063. To listen to a
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – today announced it will report financial results for the third quarter 2022 after market close on Thursday, November 3, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-289-0438 for domestic callers or 1-323-794-2423 for international callers. Please reference Conference ID: 2768596. To listen to a live webcast, please visit the
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – today announced it will report financial results for the second quarter 2022 after market close on Thursday, August 4, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-289-0720 for domestic callers or 1-323-701-0160 for international callers. Please reference Conference ID: 1255722. To listen to a live webcast, please visit the
SC 13G/A - CareDx, Inc. (0001217234) (Subject)
SC 13G/A - CareDx, Inc. (0001217234) (Subject)
SC 13G/A - CareDx, Inc. (0001217234) (Subject)
SC 13G/A - CareDx, Inc. (0001217234) (Subject)
SC 13G/A - CareDx, Inc. (0001217234) (Subject)
SC 13G - CareDx, Inc. (0001217234) (Subject)
SC 13G - CareDx, Inc. (0001217234) (Subject)
SC 13G/A - CareDx, Inc. (0001217234) (Subject)
SC 13G/A - CareDx, Inc. (0001217234) (Subject)
SC 13G - CareDx, Inc. (0001217234) (Subject)
CareDx Announces Addition of Operational and Commercial Expertise to Lead Key Strategic Initiatives Marica Grskovic Appointed Chief Strategy Officer to Lead Corporate Development CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the appointment of two senior executives who will lead key initiatives as the Company advances its long-term strategic growth plan. CareDx will be sharing its long-term growth strategy during an Investor Day in October 2024. Keith Kennedy brings more than 20 years of experience and e
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – has appointed John W. Hanna as its new President and Chief Executive Officer, and member of the Company's Board of Directors, effective April 15, 2024. "John is an outstanding leader with a proven track record of building high-performing teams that deliver consistent results. With extensive experience in the molecular diagnostics and life sciences tools industries, John is the right executive to bring strategic leadership to CareDx to propel the compan
CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that Bryan Riggsbee joins CareDx's Board of Directors, effective March 11, 2024. "We're pleased to welcome Bryan to our Board," said Michael Goldberg, CareDx Board Chairperson. "His financial expertise, operating background and deep understanding of revenue cycle management in molecular diagnostics will allow him to make meaningful contributions to our Board." Riggsbee previously served as Chief Financial Officer at Myr
Board Establishes Office of the CEO, Conducts Search for Successor Raises 2023 Revenue Guidance CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – announced today that Dr. Reginald Seeto will be stepping down from his position as Chief Executive Officer and President and resigning as a Director of the Board effective November 1, 2023, and will transition to the role of Senior Advisor to the Chairperson. CareDx will establish an Office of the CEO consisting of Board Chairperson Michael Goldberg, Chief Financial Officer Abh
CAMBRIDGE, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Grace E. Colón, Ph.D., to its Board of Directors. Dr. Colón has more than 25 years of experience as a healthcare leader, investor and entrepreneur; she most recently served as President, CEO and Director of clinical-stage biotechnology company InCarda Therapeutics, Inc. "Grace is a seasoned leader who has founded and managed multiple biotechnology and healthcare businesses," said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. "As we continue t
Cambridge, MA, June 01, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ:SMMT) today announced that Ankur Dhingra has been appointed as Chief Financial Officer, effective immediately. "We are in a pivotal time for Team Summit as we seek to expand our portfolio of pipeline assets through potential collaborations and possible acquisitions," said Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "Ankur's leadership and experience will be critical in ensuring the financial viability and excellence of our organization. Ankur's wealth of knowledge across all aspects of finance will add substantial value to our organization as we take the next step in seeking to make
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that the company has completed its transition from Peter Maag, PhD, to Reginald Seeto, MBBS, as Chief Executive Officer. Concurrent with the appointment of Dr. Seeto as President and Chief Executive Officer of CareDx in November 2020, Dr. Maag had agreed to serve as Executive Chairman of the company's Board of Directors to facilitate an orderly transition. Now that this transition is
SOUTH SAN FRANCISCO, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the appointment of patient advocate, political leader, and former state senator Art Torres to its Board of Directors. Torres began his career working alongside Cesar Chavez to fight against pesticide exposure that was killing and sickening farm workers in California. He later served for 20 years in the California legislature, chairing the State Assembly's Health Committee, and then was
TORONTO and CHICAGO, July 19, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. ("Medexus" or the "Company") (TSX:MDP) (OTCQX:MEDXF) is pleased to announce the appointment of Marcel Konrad as Chief Financial Officer of the Company, effective immediately. Mr. Konrad succeeds Roland Boivin, who is stepping down after nearly a decade in the role. Mr. Boivin has agreed to stay on in an advisory capacity in order to help ensure an orderly transition of responsibilities to Mr. Konrad over the next approximately three months. "I want to take this opportunity on behalf of all of us at Medexus to thank Roland for all of his efforts and dedicated service and to wish him the very best in his fut
Dr. Valantine brings deep transplant and diversity leadership expertise to the CareDx board SOUTH SAN FRANCISCO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announces that Hannah Valantine, MD has joined CareDx's Board of Directors. Dr. Valantine is a Professor of Medicine at Stanford and the former National Institutes of Health (NIH) Chief Scientific Officer for Scientific Workforce Diversity. Prior to joining the NIH, she was Professor of Cardiovascular Medi
Wells Fargo initiated coverage of CareDx with a rating of Underweight and set a new price target of $28.00
BTIG Research upgraded CareDx from Neutral to Buy and set a new price target of $40.00
Raymond James downgraded CareDx from Outperform to Mkt Perform
Craig Hallum upgraded CareDx from Hold to Buy and set a new price target of $15.00
Stephens upgraded CareDx from Equal-Weight to Overweight and set a new price target of $10.00
Raymond James upgraded CareDx from Mkt Perform to Outperform and set a new price target of $12.00
BTIG Research downgraded CareDx from Buy to Neutral
Stephens downgraded CareDx from Overweight to Equal-Weight and set a new price target of $9.00 from $19.00 previously
Craig Hallum downgraded CareDx from Buy to Hold and set a new price target of $9.00 from $26.00 previously
Raymond James downgraded CareDx from Strong Buy to Mkt Perform
4 - CareDx, Inc. (0001217234) (Issuer)
4 - CareDx, Inc. (0001217234) (Issuer)
4 - CareDx, Inc. (0001217234) (Issuer)
4 - CareDx, Inc. (0001217234) (Issuer)
4 - CareDx, Inc. (0001217234) (Issuer)
4 - CareDx, Inc. (0001217234) (Issuer)
4 - CareDx, Inc. (0001217234) (Issuer)
4 - CareDx, Inc. (0001217234) (Issuer)
4 - CareDx, Inc. (0001217234) (Issuer)
4 - CareDx, Inc. (0001217234) (Issuer)
Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on CareDx (NASDAQ:CDNA) in the last three months. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 1 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 4 1 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for CareDx, presenting an average target of $16.67, a high estimate of $22.00, and a low estimate of $14.00. This current average refl
Goldman Sachs analyst Matthew Sykes maintains CareDx (NASDAQ:CDNA) with a Buy and raises the price target from $14 to $16.
Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on CareDx (NASDAQ:CDNA) in the last three months. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 2 0 0 0 Last 30D 0 0 0 0 0 1M Ago 4 1 0 0 0 2M Ago 0 1 0 0 0 3M Ago 0 0 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $16.5, a high estimate of $22.00, and a low estimate of $14.00. Observing a 26.92% increase, the current average has risen from
HC Wainwright & Co. analyst Yi Chen reiterates CareDx (NASDAQ:CDNA) with a Neutral.
CareDx solutions are featured in 36 oral presentations and posters, and a symposium. The findings highlight innovative approaches, including AI integration, and the real-world clinical utility of CareDx's solutions, emphasizing their significant impact on patient care and outcomes in kidney, heart, and lung transplantation.
CareDx Reiterates Position that it Does Not Infringe Natera's ‘544 PatentInjunction Motion has No Impact on CareDx's Business or Patient and Clinician Access to AlloSure or AlloMapCareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today responded to Natera, Inc.'s filing of a motion for an injunction related to patent 11,111,544 (the ‘544 patent).The motion seeks to stop CareDx from using a prior AlloSure® process that Natera alleged infringed the ‘544 patent. That process is no longer in effect. As CareDx informed Natera and th
As of May 24, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro. Here's the latest list of major overbought players in this sector. TransMedics Group, Inc. (NASDAQ:TMDX) On April 30, TransMedics posted upbeat quarterly resul
Craig-Hallum analyst Connor Chamberlain maintains CareDx (NASDAQ:CDNA) with a Buy and raises the price target from $15 to $22.
HeartCare Results Effectively Stratified Patients at Highest Risk for Acute Cellular RejectionCardiologists Performed the Fewest Biopsies After Dual Negative HeartCare Results Compared to Single or Dual Positive ResultsTwo-Year Clinical Outcomes Data Demonstrate Excellent Survival and Allograft FunctionCareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced findings from the SHORE (Surveillance HeartCare Outcomes Registry) study, one of the largest heart transplant studies of its
S-8 - CareDx, Inc. (0001217234) (Filer)
8-K - CareDx, Inc. (0001217234) (Filer)
10-Q - CareDx, Inc. (0001217234) (Filer)
8-K - CareDx, Inc. (0001217234) (Filer)
S-8 - CareDx, Inc. (0001217234) (Filer)
8-K - CareDx, Inc. (0001217234) (Filer)
EFFECT - CareDx, Inc. (0001217234) (Filer)
POS AM - CareDx, Inc. (0001217234) (Filer)
10-Q - CareDx, Inc. (0001217234) (Filer)
8-K - CareDx, Inc. (0001217234) (Filer)